160 related articles for article (PubMed ID: 36089725)
21. Cisplatin ototoxicity in children: implications for primary care providers.
Helt-Cameron J; Allen PJ
Pediatr Nurs; 2009; 35(2):121-7. PubMed ID: 19472677
[TBL] [Abstract][Full Text] [Related]
22. [Clinical study of the ototoxicity of cisplatin].
Basterra J; Iranzo C; Marco J
An Otorrinolaringol Ibero Am; 1985; 12(2):167-72. PubMed ID: 4039901
[No Abstract] [Full Text] [Related]
23. [Research progress on the relationship between cisplatin ototoxicity and autophagy].
Liang Z; Cheng G; Zhang T; Jia H
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Feb; 34(2):189-192. PubMed ID: 32086932
[No Abstract] [Full Text] [Related]
24. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
Polski B; Sosnowska-Sienkiewicz P; Szydłowski J; Januszkiewicz-Lewandowska D
Audiol Neurootol; 2023; 28(1):32-42. PubMed ID: 36191558
[TBL] [Abstract][Full Text] [Related]
25. Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.
Okada H; Kitagawa K
Cancer Med; 2023 Apr; 12(7):7904-7910. PubMed ID: 36567514
[TBL] [Abstract][Full Text] [Related]
26. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
27. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
28. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
29. Ototoxicity of 12 mg/kg cisplatin in the Fischer 344/NHsd rat using multiple dosing strategies.
Harrison RT; Seiler BM; Bielefeld EC
Anticancer Drugs; 2016 Sep; 27(8):780-6. PubMed ID: 27467178
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1.
Turan C; Kantar M; Aktan Ç; Kosova B; Orman M; Bilgen C; Kirazlı T
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1333-1338. PubMed ID: 31586226
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin ototoxicity and protection: clinical and experimental studies.
Rybak LP; Mukherjea D; Jajoo S; Ramkumar V
Tohoku J Exp Med; 2009 Nov; 219(3):177-86. PubMed ID: 19851045
[TBL] [Abstract][Full Text] [Related]
32. [Genetic background of cisplatin induced ototoxicity].
Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections.
Hill GW; Morest DK; Parham K
Otol Neurotol; 2008 Oct; 29(7):1005-11. PubMed ID: 18716567
[TBL] [Abstract][Full Text] [Related]
34. Levosimendan ameliorates cisplatin-induced ototoxicity: Rat model.
Gozeler MS; Ekinci Akdemir FN; Yildirim S; Sahin A; Eser G; Askin S
Int J Pediatr Otorhinolaryngol; 2019 Jul; 122():70-75. PubMed ID: 30978472
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
36. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
37. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
38. Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population.
Chan SL; Ng LS; Goh X; Siow CH; Goh HL; Goh BC; Cheo T; Loh KS; Brunham LR
Head Neck; 2018 Jul; 40(7):1425-1433. PubMed ID: 29451951
[TBL] [Abstract][Full Text] [Related]
39. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
40. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
